PMID- 16552959
OWN - NLM
STAT- MEDLINE
DCOM- 20070713
LR  - 20231213
VI  - 24
IP  - 11
DP  - 2005 Nov
TI  - [In vitro stimulation of specific antileukemia T-cell response by dendritic cells 
      derived from CD14+ acute monocytic leukemia cells].
PG  - 1338-44
AB  - BACKGROUND & OBJECTIVE: Dendritic cells (DCs) or DC-like cells had been 
      successfully induced in vitro from leukemia cells, which may provide a promising 
      immunotherapeutic protocol for leukemia. This study was designed to investigate 
      the efficiency of in vitro generation of dendritic cells from CD14+ acute 
      myelomonocytic (M4) or monocytic (M5) leukemia cells and their ability of 
      stimulating specific antileukemia T-cell response. METHODS: Bone marrow 
      mononuclear cells (BMMNCs) were isolated from 5 M4/M5 leukemia patients with high 
      CD14 expression, and then divided into 3 groups: adherent leukemia cells, 
      nonadherent blasts, and total unfractioned blasts. CD14 expression of the 3 
      groups was evaluated by flow cytometry (FCM). When cultured with or without 
      granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4) 
      and tumor necrosis factor alpha (TNF-alpha) for 7-10 days, monocytic leukemia 
      cell-derived dendritic cells (Mo-LDCs) were identified through morphologic 
      observation and immunophenotype analysis using FCM. The immune function of 
      Mo-LDCs was detected through allogeneic mixed lymphocyte reaction (Allo-MLR) and 
      cytotoxicity assay of antileukemia cytotoxic T lymphocytes (CTLs). The leukemic 
      origin of Mo-LDCs was confirmed by chromosomal karyotype analysis combined with 
      the aberrant expression of myeloid antigens. RESULTS: The amount of CD14+ cells, 
      which could differentiate into CD83+ mature DCs under induction of the cytokine 
      combination, was higher in adherent leukemia cells than in nonadherent blasts and 
      total unfractioned blasts. Regarding each 3 cell groups of the same patient or 
      the unfractioned blasts of various patients, initial CD14 expression was 
      positively related to the yield of CD83+ DCs after induction (r = 0.967, P = 
      0.007). Mo-LDCs exhibited typical morphology and phenotype as mature DCs, induced 
      potent proliferation of homogeneous T cells in Allo-MLR, stimulated the expansion 
      of leukemia-specific CTLs, and continued to possess the cytogenetic abnormalities 
      of the original leukemia, as well as the aberrant expression of myeloid antigens. 
      CONCLUSIONS: In M4/M5 subtype of AML, CD14+ cells could differentiate into 
      immune-competent Mo-LDCs under the induction of the cytokine combination. CD14 
      expression level may predict the DCs differentiation ability of monocytic 
      leukemia. Mo-LDCs, which possess the classical phenotype and function of DCs, as 
      well as the abnormal leukemic antigens, may be useful for the immunotherapy of 
      M4/M5 AML.
FAU - Sheng, Li-Xia
AU  - Sheng LX
AD  - Department of Hematology, The Third Affiliated Hospital, Soochow University, 
      Changzhou, Jiangsu, 213000, PR China.
FAU - Xie, Xiao-Bao
AU  - Xie XB
FAU - Qiu, Guo-Qiang
AU  - Qiu GQ
FAU - Gu, Wei-Ying
AU  - Gu WY
FAU - Wang, Zhi-Lin
AU  - Wang ZL
FAU - Wu, Hao-Qing
AU  - Wu HQ
LA  - chi
PT  - Journal Article
PL  - China
TA  - Ai Zheng
JT  - Ai zheng = Aizheng = Chinese journal of cancer
JID - 9424852
RN  - 0 (Antigens, CD)
RN  - 0 (Immunoglobulins)
RN  - 0 (Lipopolysaccharide Receptors)
RN  - 0 (Membrane Glycoproteins)
SB  - IM
MH  - Adolescent
MH  - Aged, 80 and over
MH  - Antigens, CD/metabolism
MH  - Cell Differentiation
MH  - Cells, Cultured
MH  - Dendritic Cells/*immunology/pathology
MH  - Female
MH  - Humans
MH  - Immunoglobulins/metabolism
MH  - Leukemia, Monocytic, Acute/immunology/*pathology
MH  - Lipopolysaccharide Receptors/*analysis
MH  - Lymphocyte Activation
MH  - Lymphocyte Culture Test, Mixed
MH  - Male
MH  - Membrane Glycoproteins/metabolism
MH  - Middle Aged
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - CD83 Antigen
EDAT- 2006/03/24 09:00
MHDA- 2007/07/14 09:00
CRDT- 2006/03/24 09:00
PHST- 2006/03/24 09:00 [pubmed]
PHST- 2007/07/14 09:00 [medline]
PHST- 2006/03/24 09:00 [entrez]
PST - ppublish
SO  - Ai Zheng. 2005 Nov;24(11):1338-44.